SEMA+CAGRI
Sema/Cagri is a dual-compound research blend combining a long-acting GLP-1 receptor agonist with a long-acting amylin analog, allowing researchers to examine complementary incretin and amylin receptor pathway interactions simultaneously in controlled laboratory models. Supplied as a lyophilized powder in a 3mL vial, it is intended exclusively for in vitro laboratory research by qualified scientific personnel.
This combination has been utilized in preclinical studies examining GLP-1 and amylin receptor binding kinetics, pancreatic beta cell signaling, glucose metabolism pathway interactions, and dual receptor energy substrate regulation — independent of the broader metabolic effects associated with endogenous GLP-1 and amylin activity.
Product Details
- Form: Lyophilized powder (for laboratory research)
- Amount: 5 mg Semaglutide + 5 mg Cagrilintide per vial
- Purity: ≥ 98% (HPLC tested)
- Semaglutide: 31 amino acids, MW ~4113.6 g/mol
- Cagrilintide: 36 amino acids, MW ~3900 g/mol
- Intended Use: Laboratory research only
DISCLAIMER: This product is strictly to be used for scientific research use only. It is not for human consumption and the FDA has not approved the use for diagnostic, therapeutic, or medical purposes.
We recommend you review our Terms of Service if you have questions about product use.
